Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.

[1]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[2]  Amit G Singal,et al.  Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  R. Cabrera,et al.  Current and future treatments for hepatocellular carcinoma. , 2015, World journal of gastroenterology.

[4]  P. Hoff,et al.  Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. , 2015, Molecular and clinical oncology.

[5]  B. Pollock,et al.  Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction. , 2015, Journal of gastrointestinal oncology.

[6]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[7]  B. Sangro,et al.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use Annex 17 : Real Time Release Testing Legal basis for publishing the detailed guidelines , 2015 .

[9]  T. Mine,et al.  Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. , 2014, World journal of hepatology.

[10]  Zhongfa Zhang,et al.  Sorafenib in liver function impaired advanced hepatocellular carcinoma. , 2014, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.

[11]  M. Brose,et al.  Management of sorafenib-related adverse events: a clinician's perspective. , 2014, Seminars in oncology.

[12]  H. Monsour,et al.  Hepatocellular carcinoma: the rising tide from east to west—a review of epidemiology, screening and tumor markers , 2013 .

[13]  S. Shin,et al.  Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib. , 2013, International journal of clinical pharmacology and therapeutics.

[14]  D. Semela,et al.  Sorafenib: from literature to clinical practice. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  R. Labianca,et al.  Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  Y. Eguchi,et al.  Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib , 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

[17]  H. Blum,et al.  The role of imaging techniques in clinical decision making for the management of hepatocellular carcinoma , 2012, Hepatology.

[18]  F. Farinati,et al.  Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function , 2011, Cancer Chemotherapy and Pharmacology.

[19]  S. Truant,et al.  Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child‐Pugh score , 2011, Alimentary pharmacology & therapeutics.

[20]  C. Lathia,et al.  Effect of hepatic impairment on sorafenib pharmacokinetics: Results of a multicenter, open-label, single-dose, phase I trial. , 2011, Journal of Clinical Oncology.

[21]  S. Fan,et al.  The use of single-agent sorafenib in the treatment of patients with advanced hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis. , 2011, Journal of Clinical Oncology.

[22]  D. Amadori,et al.  Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. , 2011, Gastrointestinal cancer research : GCR.

[23]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[24]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[25]  V. Paradis,et al.  Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib , 2010, European journal of gastroenterology & hepatology.

[26]  M. Kudo,et al.  Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study , 2010, International journal of clinical practice.

[27]  T. Greten,et al.  Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. , 2010, European journal of gastroenterology & hepatology.

[28]  K. Owzar,et al.  Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  K. Soo,et al.  Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. , 2009, The Cochrane database of systematic reviews.

[30]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[31]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[32]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[33]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.